BioSpace News Archive

New research from the Abramson Cancer Center at the University of Pennsylvania, published in the May 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network,

The global eye allergy therapeutics market is expected to post a CAGR close to 5% during the period 2019-2023, according to the latest market research report by Technavio.

Regeneron Pharmaceuticals, Inc. will webcast its presentation at the Goldman Sachs 40th Annual Global Healthcare Conference at 9:20 a.m. Pacific Time on Tuesday, June 11, 2019.

Neovasc Inc. announced that new data for its Tiara™ transcatheter mitral valve replacement device and Neovasc Reducer™ device for the treatment of refractory angina were presented in several presentations at the EuroPCR 2019 Conference held this week in Paris, France.

VITAS® Healthcare, the nation’s leading provider of end-of-life care, has won 16 awards for multimedia marketing from the Aster Awards, an elite competition recognizing outstanding excellence in healthcare advertising.

Volunteers of America has launched a significant moral injury initiative by establishing the Shay Moral Injury Center.

Nordic Nanovector ASA announces its results for the first quarter 2019.

Targovax ASA announces that going forward the company will strengthen the commitment to oncolytic viruses and focus resources to advance the ONCOS program with full force.

Today, Bayer announced a five-year partnership with the World Federation of Hemophilia (WFH) Humanitarian Aid Program, which will bring education, training, and Bayer’s full portfolio of recombinant Factor VIII (rFVIII) treatments to healthcare professionals in more than 60 countries where access to care is limited.

The partner of CStone Pharmaceuticals, Agios Pharmaceuticals, Inc. announced that the global Phase 3 ClarIDHy trial of TIBSOVO in previously treated cholangiocarcinoma patients with an isocitrate dehydrogenase 1 (IDH1) mutation met its primary endpoint.